TUBB3 tubulin beta 3 class III
ENSG00000258947 · protein coding · Open Targets profile
Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:34996871, PubMed:38305685, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:34996871, PubMed:38305685, PubMed:38609661). Below the cap, alpha-beta tubulin heterodimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). TUBB3 plays a critical role in proper axon guidance and maintenance (PubMed:20074521). Binding of NTN1/Netrin-1 to its receptor UNC5C might cause dissociation of UNC5C from polymerized TUBB3 in microtubules and thereby lead to increased microtubule dynamics and axon repulsion (PubMed:28483977). Plays a role in dorsal root ganglion axon projection towards the spinal cord (PubMed:28483977). {ECO:0000269|PubMed:20074521, ECO:0000269|PubMed:28483977, ECO:0000269|PubMed:34996871, ECO:0000269|PubMed:38305685, ECO:0000269|PubMed:38609661}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.4499399960041046 (upper bound 0.6748899817466736). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against TUBB3 (paclitaxel poliglumex, glembatumumab vedotin, vinflunine, vincristine, vinorelbine, polatuzumab vedotin, ixabepilone, mirvetuximab soravtansine, vinblastine, colchicine, eribulin, enfortumab vedotin), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Elias JabbourM.D. Anderson Cancer Center · 4 of 4 trials Phase 2+Ph2NCT01424982 · Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemiabrief
- Alex F HerreraCity of Hope Medical Center · 3 of 3 trials Phase 2+
- Min YanHenan Cancer Hospital · 3 of 3 trials Phase 2+
- Seth E. KarolSt. Jude Children's Research Hospital · 3 of 3 trials Phase 2+Ph1/Ph2NCT05192889 · Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclaxbrief
- Bristol-Myers SquibbBristol-Myers Squibb · 2 of 3 trials Phase 2+Ph2/Ph3NCT04887870 · Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Studybrief
- Amar GajjarSt. Jude Children's Research Hospital · 2 of 2 trials Phase 2+
- Aristeidis KatsanosPopulation Health Research Institute · 2 of 2 trials Phase 2+
- Ashkan ShoamaneshPopulation Health Research Institute · 2 of 2 trials Phase 2+
- Binghe XuOncology Hospital, Chinese Academy of Medical Sciences · 2 of 2 trials Phase 2+
- Dai ChiharaUT MD Anderson Cancer Center · 2 of 2 trials Phase 2+
- David McCallM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Elena ParovichnikovaNational Research Center for Hematology · 2 of 2 trials Phase 2+
- Elizabeth A MullenChildren's Oncology Group · 2 of 2 trials Phase 2+
- Farhad Ravandi-KashaniSWOG Cancer Research Network · 2 of 2 trials Phase 2+
- Funda Meric-BernstamM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
Registry trials of paclitaxel poliglumex, glembatumumab vedotin, vinflunine, vincristine, vinorelbine, polatuzumab vedotin, ixabepilone, mirvetuximab soravtansine, vinblastine, colchicine, eribulin, enfortumab vedotin updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 253 of 378 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 22 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
367 trials of drugs against TUBB3 were stopped early; 16 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of paclitaxel poliglumex, glembatumumab vedotin, vinflunine, vincristine, vinorelbine, polatuzumab vedotin, ixabepilone, mirvetuximab soravtansine, vinblastine, colchicine, eribulin, enfortumab vedotin, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 367.
- terminated · 2026-11-06 · Assistance Publique - Hôpitaux de Paris · Colchicine“Sponser decision”
- terminated · 2026-10-16 · Henan Cancer Hospital · Eribulin and Tucidinostat“The anticipated efficacy was not achieved; the primary objective of Stage 1 in the Simon-2 design was not met.”
- terminated · 2026-10-15 · Spanish Breast Cancer Research Group · Vinorelbine, Eribulin“Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.”
- terminated · 2026-10-05 · Children's Oncology Group · Vincristine Sulfate“Drug supply issues”
- suspended · 2026-09-29 · University of Washington · Vincristine“Safety Review”
- withdrawn · 2026-09-24 · Case Comprehensive Cancer Center · matched by the registry's drug synonyms“PI left institution”
- terminated · 2026-09-21 · Institut Claudius Regaud · Zolinza (vorinostat), vinorelbineNo reason given
- terminated · 2026-09-18 · Pusan National University Yangsan Hospital · matched by the registry's drug synonyms“Poor accrual due to increased use of alternative neoadjuvant treatment options.”
- terminated · 2026-09-17 · Centre Oscar Lambret · Vinblastine“Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).”
- terminated · 2026-09-14 · Astellas Pharma Global Development, Inc. · Enfortumab vedotin“Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.”
- suspended · 2026-09-01 · CStone Pharmaceuticals · Vincristine“The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.”
- terminated · 2026-08-03 · Hoffmann-La Roche · Enfortumab Vedotin“Study was closed early as the sponsor decided not to continue development of certain treatment combinations.”
- terminated · 2026-07-30 · M.D. Anderson Cancer Center · Vincristine Sulfate“the study was closed early due to competing trials”
- withdrawn · 2026-06-29 · Swedish Orphan Biovitrum · matched by the registry's drug synonyms“Business decision.”
- terminated · 2026-06-12 · University Hospital, Montpellier · Colchicine“Inclusion period completed”
- terminated · 2026-05-15 · University Medicine Greifswald · Colchicine 0.5 mg Oral Tablet“The study was terminated due to an inability to reach the planned sample size, despite efforts to enhance recruitment.”
- withdrawn · 2026-05-14 · Institute of Hematology & Blood Diseases Hospital, China · matched by the registry's drug synonyms“drug-associated adverse reactions”
- terminated · 2026-05-13 · M.D. Anderson Cancer Center · Vincristine“<75% participation”
- terminated · 2026-04-16 · UNC Lineberger Comprehensive Cancer Center · Polatuzumab vedotin (PV)“Funding”
- withdrawn · 2026-04-01 · Eric Jacobsen, MD · Vincristine“Ipsen requested a temporary closure due to a safety concern.”
- terminated · 2026-03-24 · Astellas Pharma Global Development, Inc. · enfortumab vedotin (EV)“Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.”
- withdrawn · 2026-03-18 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Vincristine“Replaced with another clinical trial.”
- suspended · 2026-03-16 · National Cancer Institute (NCI) · Vincristine“Pending updated agreements in order to enroll additional participants.”
- terminated · 2026-03-12 · Allarity Therapeutics · Ixabepilone Injection“Company Decision”
- terminated · 2026-03-02 · BeiGene · matched by the registry's drug synonyms“Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.”
Paediatric incentives and obligations for TUBB3's drugs
For paclitaxel poliglumex, glembatumumab vedotin, vinflunine, vincristine, vinorelbine, polatuzumab vedotin, ixabepilone, mirvetuximab soravtansine, vinblastine, colchicine, eribulin, enfortumab vedotin: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TUBB3 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002299-PIP01-17 (Enfortumab vedotin, Treatment of urothelial carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 11 Apr 2018; EMEA-002299-PIP02-23 (Enfortumab vedotin, Treatment of head and neck epithelial malignant neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 7 Sept 2023; EMEA-003101-PIP01-21 (colchicine, Prevention of cardiovascular events): W: decision granting a waiver in all age groups for all conditions or indications, 31 Jan 2022; EMEA-001261-PIP01-11-M07 (Eribulin, Treatment of soft tissue sarcoma): PM: decision on the application for modification of an agreed PIP, 6 Dec 2021; compliance positive 25 Feb 2022; +3 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/15/1458 positive 19 Mar 2015: Treatment of ovarian cancer; EU/3/18/2013 positive 16 Apr 2018: Treatment of diffuse large B-cell lymphoma; EU/3/18/2133 positive 11 Jan 2019: Treatment of soft tissue sarcomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Polivy: authorised since 16 Jan 2020, orphan medicine; Padcev: authorised since 13 Apr 2022; Elahere: authorised since 14 Nov 2024, orphan medicine; Colchicine Agepha Pharma: authorised since 24 Jul 2026; +4 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Vincristine Sulfate, date not given: Acute leukemia; MULTIPLE (in combination); Vinblastine sulfate, 25 Nov 1965: Palliative treatment of malignancies including generalized Hodgkin’s disease, histiocytosis X and testicular germ cell carcinomaRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 766 interventional studies of paclitaxel poliglumex, glembatumumab vedotin, vinflunine, vincristine, vinorelbine, polatuzumab vedotin, ixabepilone, mirvetuximab soravtansine, vinblastine, colchicine, eribulin, enfortumab vedotin include patients under 18; 191 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 86 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.